EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Glucagon-like peptide-1 receptor agonist prevents pulmonary fibrosis following acute COVID-19 infection associated with type 2 diabetes

Runhong Zhou iD, Ming Yue, Qing Shen, Na Liu, Yuting Chen, Pui Wang, Kyungmin Kim, Ranyao Yang, Honglin Chen iD, Kwok-Yung Yuen iD, Kelvin Kai-Wang To iD, Aimin Xu und 1 weitere

Journal of Virology · 18.08.2026 · 100 (8)

DOI: 10.1128/jvi.00401-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, erschienen am 18.08.2026. Verfasst von Runhong Zhou und 12 weiteren Autor:innen. Beteiligte Einrichtung: AIDS Institute, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, P…. Hauptthemen laut MEDLINE: COVID-19, Diabetes Mellitus, Type 2, Pulmonary Fibrosis, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health@InnoHK to CVVT, Hong Kong Theme Based Research Scheme, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post-acute sequelae of COVID-19 (PASC) poses a major health burden after SARS-CoV-2 infection. Although type 2 diabetes (T2D) is associated with PASC, the mechanism of T2D-mediated PASC in the lung remains elusive. Here, we found that people with T2D (PWT2D) exhibited significantly upregulated fibrosis-related genes in monocytes, which positively correlated with pulmonary fibrosis-related biomarkers up to 3 months after acute SARS-CoV-2 infection. Using db/db mice to model human T2D, we found consistently that SARS-CoV-2 infection resulted in upregulation of fibrosis-related genes in lung macrophages and persistent pulmonary fibrosis. Moreover, the macrophage-depletion demonstrated that pro-inflammatory macrophages in db/db mice were determinants for inducing pulmonary fibrosis post-infection. Importantly, the anti-T2D glucagon-like peptide-1 receptor agonist (GLP1-RA) reprogramed macrophage responses to SARS-CoV-2 by normalizing fibrosis-related genes, significantly reducing the pulmonary fibrosis in a glucose-independent manner. These findings demonstrated that SARS-CoV-2-induced proinflammatory macrophages are detrimental factors in T2D-mediated PASC, which can be prevented by GLP1-RA. IMPORTANCE Some COVID-19 patients develop pulmonary post-acute sequelae of COVID-19 (PASC) with clinical symptoms lasting for years. Critically, the incidence of pulmonary PASC in PWT2D is four times higher than that in those without T2D. However, the immune mechanisms underlying pulmonary PASC in PWT2D remain poorly understood. Our findings demonstrate that SARS-CoV-2-induced proinflammatory macrophages are key drivers of PASC-associated pulmonary fibrosis. We further provide in vivo evidence that glucagon-like peptide-1 receptor agonists (GLP1-RAs) can reprogram pulmonary macrophages to prevent SARS-CoV-2-induced PASC in a T2D mouse model, with important implications for therapy in PWT2D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Diabetes Mellitus, Type 2Pulmonary FibrosisGlucagon-Like Peptide-1 Receptor AgonistsAnimalsMiceHumansMaleSARS-CoV-2MacrophagesPost-Acute COVID-19 SyndromeMice, Inbred C57BLLungDisease Models, AnimalFemale

Stichwörter der Autor:innen

SARS-CoV-2glucagon-like peptide-1 receptor agonistpost-acute sequelae of COVID-19proinflammatory macrophagespulmonary fibrosistype 2 diabetes

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • AIDS Institute, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.
  • Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.
  • Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, People's Republic of China.
  • Department of Infectious Disease and Microbiology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, People's Republic of China.
  • State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.
  • Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.

ORCID-Profile: Runhong Zhou, Honglin Chen, Kwok-Yung Yuen, Kelvin Kai-Wang To, Zhiwei Chen

Förderung

  • Health@InnoHK to CVVT
  • Hong Kong Theme Based Research Scheme
  • Wellcome Trust
  • Emergency Key Program Guangzhou Laboratory
  • National Key Research and Development Program of China
  • Hong Kong Research Grants Council Collaborative Research Fund
  • Health and Medical Research Fund

Zitieren

APA

Zhou, R., Yue, M., Shen, Q., Liu, N., Chen, Y., Wang, P., Kim, K., Yang, R., Chen, H., Yuen, K. Y., To, K. K. W., Xu, A., & Chen, Z. (2026). Glucagon-like peptide-1 receptor agonist prevents pulmonary fibrosis following acute COVID-19 infection associated with type 2 diabetes. Journal of Virology, 100(8). https://doi.org/10.1128/jvi.00401-26

Vancouver

Zhou R, Yue M, Shen Q, Liu N, Chen Y, Wang P, et al. Glucagon-like peptide-1 receptor agonist prevents pulmonary fibrosis following acute COVID-19 infection associated with type 2 diabetes. Journal of Virology. 2026;100(8). doi:10.1128/jvi.00401-26

BibTeX
@article{Zhou2026,
  author = {Zhou, Runhong and Yue, Ming and Shen, Qing and Liu, Na and Chen, Yuting and Wang, Pui and Kim, Kyungmin and Yang, Ranyao and Chen, Honglin and Yuen, Kwok-Yung and To, Kelvin Kai-Wang and Xu, Aimin and Chen, Zhiwei},
  title = {Glucagon-like peptide-1 receptor agonist prevents pulmonary fibrosis following acute COVID-19 infection associated with type 2 diabetes},
  journal = {Journal of Virology},
  year = {2026},
  volume = {100},
  number = {8},
  doi = {10.1128/jvi.00401-26}
}
Kostenlos starten →